Lawyers and Insurance companies have the final say, then the Oncologists...It always comes down to a legal liability concern....
It has become a time vs. price question. What good is buying here if it takes another 2 years like before to move up.
See the emphasized parenthesis..
There lies the issue to finally proclaim LB is here and accepted and of course beyond that in TROV's case " Yellow is the new Red"
Liquid biopsy: your questions answered
Which cancers will it be used for? Much of the early research has been in lung, breast and prostate cancers, but this technology is expected to have an impact on all types of cancer
When will it be available? Liquid biopsy tests are already approved and available in some countries and many more are in development; this is expected to be a major revolution in cancer testing
Are surgical biopsies now redundant? for now they are still the gold standard No –
(((((((((((. It is still relatively early days for liquid biopsy and some questions still need to be answered – for example, to what extent test accuracy varies among tumour types and stages of disease))))))))))))))
look to the left and ignore what really goes on... The whole price complaining was served up after massive short positions were placed before hand. America was ripped off again and you can bet the Clinton Trust made some bucks too!
After the revesal to the downside this past week and the rout in the IBB I would say the chances have greatly increased to see the gap in the $'s get filled. We have to ask why has other companies secured insurance coverage for their LB's when TROV has not. What is the reason? Anyone care to add?
I agree we just do not know how much was hedged. Yesterday, according to shortvolumedotcom buying outpaced selling and yet it closes down.
Hats off to Biocept for making initial headway into the insurance realm..
The question is a potential revenue generation so that the analysts providing coverage can establish forward growth on a specific test. Whether that means a larger player or not.
I initially invested in Trovagene because of the HPV test. With 14 million Americans and 79 million others throughout the world contracting contracting HPV annually, the test can be a rapid catalyst that brings in top line and bottom line revenue. So, with this in mind how many tests can TROV handle and expand upon. How much is the test? Just take a 300,000 annual HPV tests to start multiplied by $??? should add up to serious growth. So, when does it start?
I concur the question is despite the 10 X multiplier vs. blood will oncologists and the rest feel at ease telling the client we test urine vs blood. I believe it is a mindset change that is the last barrier...